Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856427 | 0.85 | ALDH1A1 (0.39) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL855372 | 0.85 | ALDH1A1 (0.39) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL22863895 | 0.84 | ALDH1A1 (0.38) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL6033729 | 0.84 | NOS2 (0.44) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL855190 | 0.80 | ALDH1A1 (0.36) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL2233696 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL11782060 | 0.76 | ADORA2A (0.42) | ALDH1A1LMNASMN1; SMN2PDE4APDE4B | |
| SCHEMBL6704220 | 0.76 | ALDH1A1 (0.42) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL12495916 | 0.75 | ALDH1A1 (0.39) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 | |
| SCHEMBL24583151 | 0.74 | ALDH1A1 (0.41) | ALDH1A1SELEVCAM1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| CN-118702672-A | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2024-04-18 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| EP-4096661-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005007647-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| US-20040054181-A1 | Synthesis of chlorinated pyrimidines | SYNGENTA CROP PROTECTION, INC. | 2004-03-18 | — | — | US | disclosed |
| CN-1449389-A | Synthesis of chlorinated pyrimidines | SYNGENTA LTD (GB) | 2003-10-15 | — | — | CN | disclosed |
| US-6608199-B2 | Such as 4,6-dichloropyrimidine and hydroxy substituted derivatives formed by reacting imidoyl chlorides with phosgene; useful in fungicides, pesticides, and pharmaceuticals | SYNGENTA LIMITED (GB) | 2003-08-19 | — | — | US | disclosed |
| EP-1301489-A2 | SYNTHESIS OF CHLORINATED PYRIMIDINES | Syngenta Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-20020055633-A1 | Synthesis of chlorinated pyrimidines | SYNGENTA LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
| WO-2002004428-A2 | SYNTHESIS OF CHLORINATED PYRIMIDINES | SYNGENTA LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | ALDH1A1 629/4885SELE 2475/4885VCAM1 4366/4885 |
| US-20040054181-A1 | Synthesis of chlorinated pyrimidines | DPYD, PDXK, NUDT1 | ALDH1A1 3187/4885SELE 4320/4885VCAM1 4772/4885 |
| US-20020055633-A1 | Synthesis of chlorinated pyrimidines | PDXK, DPYD, PFAS | ALDH1A1 3525/4885SELE 4398/4885VCAM1 4744/4885 |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | ALDH1A1 629/4885SELE 2475/4885VCAM1 4366/4885 |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | ALDH1A1 217/4885SELE 2131/4885VCAM1 2639/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | ALDH1A1 629/4885SELE 2475/4885VCAM1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.